Media365
“These ongoing reviews will promote the market development of Hong Kong while at the same time ensure sufficient investor protection is in place,” Kelvin Wong Tin-yau said in a media briefing on Tuesday. There was no timeline for when the review would be finished, he said.
Wong said the review had yet to be concluded, but the direction had been set to make sure it would allow more diverse enterprise listings under a framework introduced in 2018, which allowed pre-revenue biotechnology firms and companies with multiple voting rights to list.
“The regulatory principle here is to ensure the overall market quality of Hong Kong,” Wong said. “The reform will focus on whether it can allow more companies to list under the regime while at the same time ensuring fair treatment to investors.”
